Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous VELCADE in previously treated multiple myeloma
2008-000952-28Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2008
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall response rate after 4 cycles. Started Apr 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2008-000952-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000952-28.